SK Biopharmaceuticals said Thursday that its consolidated operating profit jumped about 112% last year to 203.9 billion won, the highest on record.
Revenue rose 29.1% from a year earlier to 706.7 billion won. Net profit increased 11.6% to 253.3 billion won.
Its main product, cenobamate (sold in the U.S. as Xcopri), posted annual U.S. sales of 630.3 billion won, up about 44% year over year. The company said the surge drove operating profit and generated about 27.0 billion won in annual royalty income.
Monthly U.S. prescriptions for cenobamate reached 47,000 in December. Total fourth-quarter prescriptions rose 6.8% from the third quarter and 29.2% from a year earlier. SK Biopharmaceuticals’ fourth-quarter revenue increased 19.2% from a year earlier to 194.4 billion won, while operating profit fell 34% to 46.3 billion won. The company said prescriptions held up, but year-end seasonality and in-transit inventory kept results around the prior quarter’s level.
SK Biopharmaceuticals said it is focusing on expanding prescriptions through its direct sales and marketing in the U.S. market. It also said it plans to use cash flow from cenobamate to broaden its research and development portfolio in central nervous system treatments, radiopharmaceutical therapeutics and targeted protein degradation.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.